EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial (Q34403098)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial |
scientific article |
Statements
1 reference
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial (English)
1 reference
Robert H Dworkin
1 reference
Andrew S C Rice
1 reference
Tom D McCarthy
1 reference
Praveen Anand
1 reference
Chas Bountra
1 reference
Philip I McCloud
1 reference
Julie Hill
1 reference
Geoff Kitson
1 reference
Nuket Desem
1 reference
Milton Raff
1 reference
EMA401-003 study group
1 reference
5 February 2014
1 reference
Identifiers
1 reference